1-3 of 3
Camillo Porta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

David J. Kwiatkowski, Toni K. Choueiri, André P. Fay, Brian I. Rini, Aaron R. Thorner, Guillermo de Velasco, Magdalena E. Tyburczy, Lana Hamieh, Laurence Albiges, Neeraj Agarwal, Thai H. Ho, Jiaxi Song, Jean-Christophe Pignon, Pablo M. Barrios, M. Dror Michaelson, Eliezer M. Van Allen, Katherine M. Krajewski, Camillo Porta, Sumanta Kumar Pal, Joaquim Bellmunt, David F. McDermott, Daniel Y.C. Heng, Kathryn P. Gray, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2445–2452.
https://doi.org/10.1158/1078-0432.CCR-15-2631
Published: 12 May 2016
View article titled, Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts

Pietro Bertino, Federica Piccardi, Camillo Porta, Roberto Favoni, Michele Cilli, Luciano Mutti, Giovanni Gaudino
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 541–548.
https://doi.org/10.1158/1078-0432.CCR-07-1388
Published: 25 January 2008
View article titled, Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts
Open the PDF for Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts in another window
Journal Articles

Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma

Andrea Sartore-Bianchi, Fabio Gasparri, Arturo Galvani, Linda Nici, James W. Darnowski, Dario Barbone, Dean A. Fennell, Giovanni Gaudino, Camillo Porta, Luciano Mutti
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5942–5951.
https://doi.org/10.1158/1078-0432.CCR-07-0536
Published: 01 October 2007
View article titled, Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent <em>In vivo</em> Activity in Mesothelioma
Open the PDF for Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent <em>In vivo</em> Activity in Mesothelioma in another window